BLOCK PCNSL (NHL32): This phase II study is trying to determine if standard chemotherapy induction therapy followed by immunotherapy (pembrolizumab) will be effective in maintaining life expectancy with minimal side effects for people with primary central nervous system lymphomaAn ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma

Summary

All participants in this trial will receive chemotherapy induction therapy (CIT) of either A) Rituximab, Methotrexate, Procarbazine & Vincristine (R-MPV) Cytarabine (Ara-C); or B) Cytarabine, Thiopeta & Rituximab (MATRix). The CIT given is at the discretion of the participant's clinician and is not assessed as part of this study. Once the induction treatment is complete, participants will receive Pembrolizumab immunotherapy (200mg via intravenous infusion) commencing 4-6 weeks after last CIT exposure, and administered every 3 weeks for 35 cycles/2 years.